A Recombinant Antibody to EphA3 for the Treatment of Hematologic Malignancies: Research Update and Interim Phase 1 Study Results
A. Hagey, Jonathan A. Leff, Varghese Palath(Sunesis (United States)), Dan Shochat, Jeffrey E. Lancet(Cornell University), Martin Lackmann(Monash University), Andy Boyd(The University of Texas at San Antonio Health Science Center), Geoffrey Yarranton, Andrew H. Wei(The Royal Melbourne Hospital), Christopher Bebbington(Curtin University), Jörge E. Cortes(Augusta University Health)
Cited by 6
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k